IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm

Associated Press
Ethiopia rebuffs US call to pull outside forces from Tigray
Ethiopia's government is rebuffing calls by the United States to withdraw troops from the embattled Tigray region. In response to U.S Secretary of State Antony Blinken's call for Ethiopia to immediately withdraw troops from Tigray, Ethiopia's foreign ministry said that it is a matter to be decided by the Addis Ababa government, not a foreign power. “It should be clear that such matters are the sole responsibility of the Ethiopian government,” Ethiopia's foreign ministry said in a statement issued Sunday.
2m ago
PR Newswire
Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
At a virtual meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS) will outline how the company expects to lead as a new kind of healthcare company with a unique and differentiated business model, high-quality operational platform and clear focus on ensuring its sustainability priorities and financial commitments are met.
2m ago
GlobeNewswire
Form 8.3 - Idox Plc
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Investec Wealth & Investment(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Idox Plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure26th February 2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”NO 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled:8,186,9881.85% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL:8,186,9881.85% All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant securityPurchase/sale Number of securitiesPrice per unit Ordinary Shares Sale 364,000 71.2p (b) Cash-settled derivative transactions Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercise Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” N/A (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” N/A (c) Attachments Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure:1st March 2021 Contact name:Phil Beardwell Chartered FCSITelephone number:020 7597 1356 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
3m ago
Deadline
Ampersand Fiction Boards International Rights On Russian Hit Crime Series ‘The Dead Lake’
EXCLUSIVE: Ampersand Fiction, the TV drama wing of Paris-based sales company Ampersand, is teaming with Russia’s 1-2-3 Production and GPM Entertainment Television to handle international distribution on crime thriller series The Dead Lake, which was a hit for Netflix in 2020. Directed by Roman Prygunov (Dukhless) and written by Roman Kantor, the scriptwriter behind the Netflix […]
4m ago
Associated Press
Iranian lawmakers visit restive southeast area after unrest
Iranian lawmakers on Monday visited an impoverished southeastern province that has been roiled by recent unrest, state-run media reported, the government's most visible step yet to address rising popular resentment in the region. Five members of parliament, including from the influential committee for national security and foreign policy, arrived in the province of Sistan and Baluchestan to investigate the turmoil, state-run IRNA news agency reported. Last week, border guards shot at fuel smugglers trying to cross into Iran from Pakistan, killing at least two and sparking protests across the city of Saravan.
5m ago
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and development collaboration with Janssen through third integrin program Conference call today at 8:00 a.m. ET WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2020. 2020 and Recent Corporate Highlights Filed first IND of an oral integrin drug candidate, MORF-057, generated by Morphic’s MInT Platform and initiated first clinical study of MORF-057 in healthy volunteers in Phase 1 clinical trial of oral IBD candidate, MORF-057, after acceptance of IND by Food and Drug AdministrationAnnounced positive preliminary results from Phase 1 single ascending dose portion of MORF-057 Phase 1 clinical trial including: MORF-057 well tolerated in all five dose cohorts ranging from 25 mg to 400 mgMORF-057 achieved greater than 95% mean receptor occupancy of α4β7 at the three highest dose levelsPhase 1 multiple ascending dose and food effect trials ongoing with full data anticipated to be presented mid-year 2021 Received $20 million payment upon AbbVie exercise of a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors, including the compounds MORF-720 and MORF-627Expanded research and development collaboration with Janssen through a third integrin programPresented promising preclinical data supporting MORF-057 as an oral integrin targeting α4β7 at UEG Week 2020, Digestive Disease Week 2020, European Crohn’s and Colitis Organization (ECCO)Advanced novel integrin-targeted candidates generated by the MInT Platform against integrins αvβ1 and αvβ8 for the treatment of fibrosis and cancerEnded the year with $228.3 million in cash and equivalents and marketable securities, providing runway into 2023 “The past year challenged how we work and live but the Morphic team came together to drive tremendous advances in the creation of oral integrin therapies. Most notably in 2020, our lead oral candidate in IBD, MORF-057, completed preclinical testing with strong proof-of-concept and entered the clinic. In an important milestone for Morphic, we have already delivered positive preliminary results from the MORF-057 Phase 1 trial. The data show a favorable tolerability profile as well as strong pharmacodynamic data that suggest α4β7 inhibition may be on par with the approved intravenous blockbuster, vedolizumab. Further, we expanded our strategic collaborations with AbbVie and Janssen to explore a broader scope of integrin drug targets and potentially boost our partnered pipeline,” commented Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic. “In the year ahead, with a strong financial base, we are able to focus on advancing the clinical development of MORF-057 and our promising preclinical programs targeting αvβ1 and αvβ8, as well as continuing to expand the MInT Platform that generates this pipeline of novel integrin therapeutic candidates.” Financial Results for the Full Year 2020 Net loss for the year ended December 31, 2020, was $45.0 million or $1.47 per share compared to a net loss of $43.3 million or $2.69 per share Revenue was $44.9 million for the year ended December 31, 2020 compared to $17.0 million for the year ended December 31, 2019. The increase was mainly due to AbbVie’s option exercise on our αvβ6 integrin inhibitor program in the third quarter of 2020 for $20 millionResearch and development expenses were $73.6 million for the year ended December 31, 2020 as compared to $53.7 million for the year ended December 31, 2019. The increase was primarily attributable to higher development and manufacturing costs associated with our lead product candidates, MORF-057 and MORF-720, as well as increased personnel-related costs to support continued progress with the company’s pipelineGeneral and administrative expenses were $18.5 million for the year ended December 31, 2020, compared to $10.2 million for the year ended December 31, 2019. The increase was primarily attributable to increased headcount and higher professional and consulting fees associated with ongoing business activities and Morphic’s operating as a public company As of December 31, 2020, Morphic had cash, cash equivalents and marketable securities of $228.3 million, compared to $237.0 million as of December 31, 2019. Morphic believes its cash, cash equivalents and marketable securities as of December 31, 2020, will be sufficient to fund operating expenses and capital expenditure requirements into 2023. About Morphic Therapeutic Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s or our partners’ plans or ability to develop, obtain approval for any indication or disease and/or commercialize any oral small-molecule integrin therapeutics, including MORF-057, MORF-720, MORF-627, and any other candidates in development, the ability of MORF-057 to treat inflammatory bowel disease, the ability of MORF-720 and MORF-627 to treat idiopathic pulmonary fibrosis as well as other fibrotic diseases, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. Statements including words such as “believe,” “plan,” “continue,” “expect,” “will be,” “develop,” “signal,” “potential,” “anticipate” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause Morphic’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Morphic’s ability to develop, obtain regulatory approval for and commercialize MORF-057, MORF-720, and other product candidates, the timing and results of preclinical studies and clinical trials, the potential impact of the COVID-19 pandemic, Morphic’s ability to protect intellectual property; and other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law. Webcast and Conference Call Morphic will host a webcast and conference call at 8:00 a.m. ET today to discuss financial and operational results for fiscal year 2020 and the MORF-057 interim data from the SAD portion of ongoing MORF-057 Phase 1 clinical trial. A live webcast of the call will be available on the Investors section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference call. To participate in the live conference call, please use the following dial-in information:US or Canada Toll-Free Dial-In Number: (844) 954-0202International Dial-In Number: (661) 407-1533Conference ID: 6992416 FINANCIAL TABLES TO FOLLOW Morphic Holding Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data) Year Ended December 31, 2020 2019 Collaboration revenue $44,945 $16,977 Operating expenses: Research and development 73,630 53,732 General and administrative 18,495 10,233 Total operating expenses 92,125 63,965 Loss from operations (47,180) (46,988)Other income: Interest income, net 1,630 4,666 Other expense, net (19) (94)Total other income, net 1,611 4,572 Loss before provision for income taxes (45,569) (42,416)Benefit from (provision for) income taxes 570 (912)Net loss $(44,999) $(43,328)Net loss per share, basic and diluted (1.47) (2.69) Weighted average common shares outstanding, basic and diluted 30,594,897 16,101,928 Morphic Holding Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) December 31,2020 December 31,2019Assets Cash, cash equivalents and marketable securities $228,264 $237,016 Other current assets 11,171 6,557 Total current assets 239,435 243,573 Other assets 2,947 3,862 Total assets $242,382 $247,435 Liabilities and Stockholders' Equity Current liabilities $39,438 $35,350 Long-term liabilities 57,747 71,167 Total liabilities 97,185 106,517 Total stockholders' equity 145,197 140,918 Total liabilities and stockholders' equity $242,382 $247,435 Contacts Morphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718 Media ContactTom Donovan, Ten Bridge Communicationstom@tenbridgecommunications.com 857.559.3397
5m ago
GlobeNewswire
Tyson Foods to Vaccinate Thousands of Iowa Workers
Free, on-site vaccinations will be offered by the companySPRINGDALE, Ark., March 01, 2021 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) will offer free, onsite COVID-19 vaccinations to thousands of frontline team members at its Iowa plants this week. The vaccines are being provided in conjunction with local health departments across the state of Iowa, where food processing workers are among the priority group now eligible for vaccination. “We’ve been working with Matrix Medical, Hy-Vee and health department officials across Iowa to prepare for this moment and we’re ready,” said Tom Brower, senior vice president of Health and Safety for Tyson Foods. “We’re pleased to offer our team members convenient access to the vaccine, and we appreciate the state of Iowa recognizing the essential role they play in feeding the world.” Tyson Foods officials expect many of the company’s 13,000 Iowa employees to be vaccinated during vaccination events later this week at or near company facilities in Columbus Junction, Council Bluffs, Independence, Perry, Sioux City, Storm Lake and Waterloo. More than 2,000 of the company’s U.S employees were recently vaccinated either at onsite events or through an external source. Approximately 800 team members were vaccinated February 19 and 20 at Tyson’s Joslin, Ill., beef plant. Photos and video of the Joslin event are available for download. Additional vaccination events are planned this week for Tyson team members in Wilkesboro, North Carolina, Albany, Kentucky and Noel, Missouri. In preparation for vaccinations, Tyson Foods has been providing expert resources and education about the vaccine to team members. This information is available in multiple languages and team members also have access to a hotline to ask questions. In addition to offering free, on-site vaccinations, the company also recently announced that it is compensating workers for up to four hours of regular pay if they are vaccinated outside of their normal shift or through an external source. Tyson Foods’ vaccination efforts are the latest in a series of measures the company has taken to fight COVID-19. Since the spring of 2020, the company invested hundreds of millions of dollars to transform its U.S. facilities with protective measures, from walk-through temperature scanners and workstation dividers to social distance monitors and always-on testing, as well as provide additional team member pay and benefits. Tyson Foods has also expanded its health services staff, added a chief medical officer and plans to pilot health clinics for team members and their families early this year. Tyson Foods continues to experience success in its efforts to protect workers from the virus. The incidence of the virus involving the company’s U.S. team members remains low. About Tyson FoodsTyson Foods, Inc. (NYSE: TSN) is one of the world’s largest food companies and a recognized leader in protein. Founded in 1935 by John W. Tyson and grown under three generations of family leadership, the company has a broad portfolio of products and brands like Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, Aidells®, ibp®, and State Fair®. Tyson Foods innovates continually to make protein more sustainable, tailor food for everywhere it’s available and raise the world’s expectations for how much good food can do. Headquartered in Springdale, Arkansas, the company has 139,000 team members. Through its Core Values, Tyson Foods strives to operate with integrity, create value for its shareholders, customers, communities and team members and serve as a steward of the animals, land and environment entrusted to it. Visit TYSONFOODS.COM to learn more. Contact: Derek Burleson, 479-290-6466
5m ago
Motley Fool
Why Facebook Is Removing False Claims About COVID and Vaccines
KX Jin explains Facebook's strategy of promoting accurate information about the pandemic and removing debunked claims.
5m ago
Business Wire
Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference
Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021.
5m ago
GlobeNewswire
The hyperscale data center market is expected to grow at a CAGR of 3.38% over the forecast period (2021 - 2026)
Hyperscale datacenters can be termed as a facility owned by the companies to offer cloud spaces for cloud computing and big data storage. It has at least 500 storage cabinets covering 10,000 Sq. Ft of space and has over 5,000 servers conected with an ultra-high-speed fiber network and offers with infrastructural cost to the end-user.New York, March 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hyperscale Datacenter Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06028501/?utm_source=GNW - Data in the recent past was considered as the foundation of an emerging economy. Almost all enterprises are using more data than what they did before and will probably consume even more data in the future. This rapidly increasing generation of data has to be stored and accessed from somewhere.- This reality has driven the rise of hyperscale data centers, which are a super-sized version of the mission-critical facilities that consist of the servers powering the Internet. Increasing cloud workloads have influenced companies like Amazon Web Services, Google, Microsoft, Facebook, and Apple to invest huge sums, around USD 1 billion to USD 3 billion, in a single campus to bring out the utmost efficiency.- The upsurge of hyperscale computing is all about businesses and their association with their data and IT operations. Companies/enterprises do not want to spend millions of dollars to build and operate a data center.- Some of the key drivers that are directly influencing the hyperscale data center growth are cloud computing, software platforms, social media, and content delivery. Social media has evolved to be a powerful tool, with over 2.28 billion users worldwide, generating volumes of data in the form of blogs, tweets, updates, images, and videos.- According to Cisco Systems, the global IP data traffic increased from 96,054 petabytes per month in 2016 to 150,910 petabytes per month in 2018 and is anticipated to reach 278,108 petabytes per month by 2021.- Further, the growing volume of Big Data across the business eco-system is gaining maturity. A recent study by Accenture in May 2018 stated that 79% of enterprise executives agreed that companies that do not embrace Big Data would lose their competitive position and are expected to face extinction. Currently, 83% of enterprises pursue Big Data projects to seize a competitive edge.- The emergence of Data-as-a-Service (DaaS) is also an indication of the increasing penetration of data across end users, an area still in the early stages of formalization, according to Oracle. Also, the number of data providers, particularly in web-sourced data, is constantly increasing, adding to the growth of the market.Key Market TrendsEnterprises to Hold Major Share- In recent times, workloads in large enterprises are being consolidated into larger and more efficient facilities, and it has become commonplace for hyperscale companies like Amazon Web Services, Google, Facebook, Microsoft, and Apple to invest USD 1 billion to USD 3 billion in a single campus.- This trend is part of the larger densification of America’s IT infrastructure, which will include data centers in many new and unexpected places.- The upsurge of hyperscale computing is all about businesses and their association with their data and IT operations. Enterprises do not want to spend millions of dollars to build and operate a data center.- Further, the growing volume of Big Data across the business eco-system is gaining maturity. A recent study by Accenture in May 2018 stated that 79% of enterprise executives agreed that companies that do not embrace Big Data would lose their competitive position and are expected to face extinction. Currently, 83% of enterprises pursue Big Data projects to seize a competitive edge. This has increased the demand for hyperscale data centers among the enterprises.United States to Dominate the Market- The United States has continued its growth in data center infrastructure solutions. Modular data center investments in tier-2 cities is expected to drive the installation of center facilities, especially for local users, which is driving the growth of the data center cooling market.- In the United States, the rate of adoption of cloud-based computing is rapidly increasing, owing to which, data centers are increasing in the country. According to Credit Suisse, the United States accounts for the highest number of hyperscale data centers worldwide, by holding about 40% in the country.- Several efforts have been made by the United States to modernize its infrastructure. In a plan to achieve this, the US Army is planning to spend up to USD 249 million to deploy private cloud computing services and data centers. General Dynamics HP and Northrop Grumman are among the service providers selected for the Army Private Cloud contract, which will provide cloud computing services to consolidate data centers using a secure private cloud.- Businesses in the United States stand to benefit from the data centers because fir purposes of the US Federal Communications Commission compliance certification, the data center is considered one unit (rather than several discrete systems). This will result in cost benefits and convenience, thereby lessening the burden on users.- The United States is home to many tech giants, such as Apple, Amazon, Microsoft, and Facebook, offering hyperscale data centers. Also, the volume of Big Data is tremendously increasing; moreover, companies are adopting new strategies to ascend several data centers.- The companies in the country are extensively investing in AI infrastructure, which demands the need for immediate processing of vast amounts of data being acquired on a real-time basis. Also, the governments in the region are taking initiatives to adopt upcoming technologies. In February 2019, the US government announced the Artificial Intelligence Initiative to prioritize AI investments in research and development, increase access to federal data and models for that research, and prepare workers to adapt to the era of AI.Competitive LandscapeThe market for hyperscale datacenters is highly consolidated because of the dominance by a few key companies in the market. Also, the barrier for new entrants is high due to the requirement of the high initial cost to enter into the market. These are companies that are continuously investing in making strategic partnership and acquisition to gain more market share. Some of the recent developments by the companies are listed below.- January 2020- Microsoft Corporation announced a partnership with AT&T for enabling next-generation solutions on the edge. The partnership is aimed at enabling new 5G, cloud, and edge computing solutions to drive enterprise capabilities for companies around the world.- September 2019 - EdgeConneX, a data center solution provider, declared a partnership with Lume to leverage its Cloud Anyware services. The partnership enables the company to accomplish goals like bringing its cloud solutions to the Edge, local and highly proximate to its enterprise customers.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06028501/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
6m ago
Investor's Business Daily
Dow Jones Futures Signal Stock Market Rally Isn't Over; Nio, Zoom On Tap
Futures rose solidly. The stock market rally faces a big test after heavy losses last week. Here's what investors should be doing now.
6m ago
GlobeNewswire
Global 5G IoT Market Report 2020-2027: Lack of Research and Innovation and High Upfront Costs for Infrastructural Establishment are Limiting the Market Growth
Dublin, March 01, 2021 (GLOBE NEWSWIRE) -- The "5G IoT Market Share, Size, Trends, Industry Analysis Report, By Radio Technology; By Range; By Vertical; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global 5G IoT market size is expected to reach USD 11.35 billion by 20275G network provides a smooth communication and networking functions and works under a wireless high-frequency technology. In addition, the technology provides an advanced, improved flexibility of wireless services, higher network speed, and reduced latency. IoT devices such as wireless sensors, computer devices, software, actuators, and others largely depend on prompt communication and data transfer services, which is provided through this technology.Moreover, it offers improved flexibility of wireless services and are largely dependent on instant communication & data transfer provided through 5G technology. It plays a vital role in the evolution of communication as well as in the businesses and society in the market. For instance, in order to obtain measurements from a boiler or other equipment in manufacturing industry, 5G IoT offers ultra-reliable communications for several time-sensitive communications processes.Increased demand for manufacturing & adoption of this technology will not only provide reliable networks but also deliver fantastic secure connection for Industrial IoT by assimilating security into the network architecture. Moreover, factors such as rise in demand for processing of collected data via sensors, analyzing, and real-time tracking of business operations & other activities across several industrial sectors are some of the other factors fueling the market growth. Furthermore, with providing backing operations that require real-time access to data changes instantly and increased demand for ultra-low latency from numerous sectors are some of the factors driving the market growth.However, lack of research and innovation and high upfront costs for infrastructural establishment are limiting the market growth. On the contrary, consumer landscape and changing business environment are expected to provide lucrative opportunities to the global market in the upcoming years. For instance, in 2019, Microsoft has announced a partnership with AT&T, which is a multinational conglomerate holding company in order to unlock 5G scenarios via its Azure Edge Zones. In addition, the partnership aimed at operating and extending its service using 5G and LTE networks. The Azure Private Edge Zones solutions helps in providing high-security applications such as factory IoT & robotics management, private smart grid for hospitals, among others.Market participants such as Anritsu, AT&T, Bell Canada, BT Group, Ericsson, Etisalat, Huawei, Juniper Networks, Inc., Nokia, Palo Alto Networks, Inc., Qualcomm Technologies, Inc., Rogers, Sierra Wireless, Singtel, Sprint, Syniverse Technologies LLC, Telefonica, Telenor Group, Telstra, Telus, Verizon, and Vodafone, among others. are some of the key players operating in the global market.Key players in the market are focusing on launching new products & developing existing offering and have adopted various strategies to expand their foothold in the market. Also, governments in countries such as U.S., South Korea, China, Japan, among others are expected to largely adopt & implement 5G IoT technology in the coming years. For instance, Nokia and Korea Telecom (KT) has collaborated to conduct trails of 5G NFV and network slicing which will allow to provide innovative services, including virtual reality, smart factory, IoT use cases and connected cars. Qualcomm Technologies, Inc. recently announced 212 LTE IoT modem, single mode, NB2 IoT chipset which allows for less power consumption.Key Topics Covered: 1. Introduction2. Executive Summary3. Research Methodology4. 5G IoT Market Insights4.1. 5G IoT - Industry snapshot4.2. 5G IoT Market Dynamics4.2.1. Drivers and Opportunities4.2.1.1. Surge in installation of 5G networks4.2.1.2. Favorable government initiatives4.2.2. Restraints and Challenges4.2.2.1. Operational issues4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.5. 5G IoT Market Industry trends5. 5G IoT Market Assessment by Radio Technology5.1. Key Findings5.2. Introduction5.3. 5G NR Standalone Architecture5.4. 5G NR Non- Standalone Architecture6. 5G IoT Market Assessment, by Range6.1. Key Findings6.2. Introduction6.3. Short Range IoT Devices6.4. Wide Range IoT Devices7. 5G IoT Market Assessment by Vertical7.1. Key Findings7.2. Introduction7.3. Manufacturing7.4. Energy & Utilities7.5. Government7.6. Healthcare7.7. Transportation & Logistics7.8. Mining8. 5G IoT Market Assessment by Geography8.1. Key findings8.2. Introduction8.2.1. 5G IoT Market Assessment, By Geography, 2020-2027 (USD Million)9. Competitive Landscape9.1. Expansion and Acquisition Analysis9.1.1. Expansion9.1.2. Acquisitions9.2. Partnerships/Collaborations/Agreements/Exhibitions10. Company Profiles AnritsuAT&TBell CanadaBT GroupEricssonEtisalatHuaweiJuniper Networks Inc.NokiaPalo Alto Networks Inc.Qualcomm Technologies Inc.RogersSierra WirelessSingtelSprintSyniverse Technologies LLCTelefonicaTelenor GroupTelstraTelusVerizonVodafone For more information about this report visit https://www.researchandmarkets.com/r/7qnmr9 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
7m ago
Country Living
20 best air purifying plants for the home
These gorgeous species will help to filter out toxic chemicals
8m ago
PR Newswire
Cantargia provides business updates at investor conferences during March 2021
Cantargia AB ("Cantargia") will participate at several international investor conferences during March to present the company, the drug candidates CAN04 and CAN10 and future plans. For details, see below.
8m ago
Associated Press
Cardlytics: 4Q Earnings Snapshot
ATLANTA (AP) _ Cardlytics, Inc. (CDLX) on Monday reported a fourth-quarter loss of $6.8 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Atlanta-based company said it had a loss of 24 cents. The results fell short of Wall Street expectations.
9m ago
BBC
Nigeria's school abductions: Why children are being targeted
A reward system for kidnappers is fuelling mass abductions of students in northern Nigeria.
9m ago
USA TODAY
6-year-old boy was killed, thrown into the Ohio River, police say. His mom is charged with murder.
Police say 6-year-old James Robert Hutchinson was killed and thrown into the Ohio River. His mother, Brittany Gosney, and her boyfriend are charged.
10m ago
WABC – NY
AG to investigate Cuomo allegations
The state of New York is awaiting Governor Andrew Cuomo's next move after he denied sexual harassment claims by a second accuser and also conceded some of his actions might have been inappropriate.
10m ago
GlobeNewswire
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
-- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications – -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- SPARTA, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products. PLx announced today that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. “The approval of the VAZALORE sNDAs marks a significant milestone that brings us closer to providing an innovative aspirin to millions of patients who need reliable and predictable antiplatelet therapy,” stated Natasha Giordano, President and Chief Executive Officer of PLx. “We are delighted that the FDA approved both sNDAs for VAZALORE, and we are eager to implement our commercial launch plans later this year. We look forward to introducing VAZALORE to the medical community and to patients who can benefit from this breakthrough technology designed to reduce the risk of stomach injury,” concluded Giordano. In October 2020, the Company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg. About VAZALORE VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. About PLx Pharma Inc.PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx Pharma believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com. Forward-Looking Statements Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property, risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov. Other risks and uncertainties are more fully described in PLx’s Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020, and in other filings that PLx has made or will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements. Contact Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: PLx Pharma Inc.
10m ago
GlobeNewswire
INNSUITES HOSPITALITY TRUST (IHT) FISCAL SECOND QUARTER
Phoenix, AZ, March 01, 2021 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE American: IHT) IHT CLEAN ENERGY DIVERSIFICATION PROGRESS InnSuites Hospitality Trust (IHT) reported fiscal 2021 second quarter revenues of approximately $1 million for the three months May 1, 2020 to July 31, 2020 compared to revenues of approximately $1.54 million for the same prior year period. Basic earnings per share for the three months ended July 31, 2020 was ($0.14) compared with ($0.05) for the three months ended July 31, 2019. This decline was largely attributable to the negative impact of the Covid-19 virus pandemic. In 2019, InnSuites Hospitality Trust (IHT) made an initial $1 million bond diversification investment convertible into 1 million shares of privately held UniGen Power, Inc. (UPI), a company developing a patented high profit potential new efficient clean energy generation innovation. In addition to the initial investment which could be converted into 1 million UPI shares, IHT also holds 2 Million warrants convertible into an additional 2 million UPI shares, which could result in IHT holding an approximate 25% ownership in UPI in the future. IHT is informed that UPI has made positive progress to date on development of this innovation, with the first Prototype scheduled to be operational on or before June 30, 2021. James Wirth, President /CEO /chairman of IHT cautioned of the challenges of any new innovation but indicated confidence in the technical team based in Detroit and in the encouraging progress over the last 14 months despite the Covid-19 pandemic. Hospitality industry results for IHT for the second fiscal quarter of Fiscal 2021, reflected the continued economic and travel industry slowdown caused by the Virus and various travel and lockdown restrictions. The sense of IHT Management, according to James Wirth President, CEO, and Board Chairman, is that the IHT stock is trading below its true underlying value based on IHT stock being closely held, the company capitalization being small, recent substantial profits coming from asset sales well above low book value, as well as IHT continuing assets held at low book values believed to have substantially higher market value, indicating substantial future profit potential. The Trust strategy of pursuing the highly promising UniGen diversification, and/or a larger reverse merger partner seeking a NYSE American listing is progressing. For more information, visit www.innsuitestrust.com. Forward-Looking Statements With the exception of historical information, the matters discussed in this news release may include “forward-looking statements” within the meaning of the federal securities laws. All statements regarding IHT’s review and exploration of potential strategic, operational and structural alternatives and expected associated costs and benefits are forward-looking. Actual developments and business decisions may differ materially from those expressed or implied by such forward-looking statements. Important factors, among others, that could cause IHT’s actual results and future actions to differ materially from those described in forward-looking statements include the uncertain outcome, impact, effects and results of IHT’s review of strategic, operational and structural alternatives, IHT’s success in finding potential qualified purchasers for its hospitality real estate, or a reverse merger partner, and other risks discussed in IHT’s SEC filings. IHT expressly disclaims any obligation to update any forward-looking statement contained in this news release to reflect events or circumstances that may arise after the date hereof, all of which are expressly qualified by the foregoing, other than as required by applicable law. FOR FURTHER INFORMATION:Marc Berg, Executive Vice President 602-944-1500 email: mberg@innsuites.com INNSUITES HOTEL CENTRE1730 E. NORTHERN AVENUE, #122Phoenix, Arizona 85020Phone: 602-944-1500
10m ago

Latest Stories